RecruitingPhase 1NCT06632236

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Cancer Research, United Kingdom
Principal Investigator
Juanita Lopez, MD, PhD
National Health Service, UK
Intervention
Amivantamab(drug)
Enrollment
12 enrolled
Eligibility
16 years · All sexes
Timeline
20242027

Study locations (2)

Collaborators

Royal Marsden NHS Foundation Trust · Cambridge University Hospitals NHS Foundation Trust · Janssen Pharmaceutica N.V., Belgium · Cancer Research UK · Minderoo Foundation · University of Cambridge

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06632236 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials